Bicara Therapeutics Inc (NASDAQ: BCAX) is -43.17% lower on its value in year-to-date trading and has touched a low of $7.80 and a high of $28.09 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BCAX stock was last observed hovering at around $9.25 in the last trading session, with the day’s gains setting it 0.65%.
Currently trading at $9.90, the stock is -21.53% and -22.17% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.05 million and changing 7.03% at the moment leaves the stock -40.49% off its SMA200. BCAX registered a loss of -51.59% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $12.7842 and a 200-day simple moving average (SMA200) of $16.672949.
The stock witnessed a -32.70% gain in the last 1 month and extending the period to 3 months gives it a -22.05%, and is 6.80% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.12% over the week and 13.29% over the month.
Distance from 52-week low is 26.92% and -64.76% from its 52-week high.
The EPS is expected to grow by 42.88% this year, but quarterly earnings will post 0.00% year-over-year.
Bicara Therapeutics Inc (BCAX) Top Institutional Holders
126.0 institutions hold shares in Bicara Therapeutics Inc (BCAX), with institutional investors hold 101.00% of the company’s shares. The shares outstanding are 54.53M, and float is at 32.77M with Short Float at 22.63%. Institutions hold 89.24% of the Float.
Bicara Therapeutics Inc (BCAX) Insider Activity
The most recent transaction is an insider sale by Meisner Lara, the company’s Chief Legal Officer. SEC filings show that Meisner Lara sold 79,146 shares of the company’s common stock on Mar 14 ’25 at a price of $12.90 per share for a total of $1.02 million. Following the sale, the insider now owns 0.0 shares.
Still, SEC filings show that on Sep 16 ’24, RA CAPITAL MANAGEMENT, L.P. (Director) acquired 1,833,000 shares at an average price of $18.00 for $32.99 million. The insider now directly holds 4,303,418 shares of Bicara Therapeutics Inc (BCAX).
